147 related articles for article (PubMed ID: 21968665)
21. The comparison between intradermal injection of abobotulinumtoxinA and normal saline for face-lifting: a split-face randomized controlled trial.
Wanitphakdeedecha R; Ungaksornpairote C; Kaewkes A; Rojanavanich V; Phothong W; Manuskiatti W
J Cosmet Dermatol; 2016 Dec; 15(4):452-457. PubMed ID: 27647769
[TBL] [Abstract][Full Text] [Related]
22. Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration.
Nestor M; Ablon G; Pickett A
Aesthet Surg J; 2017 May; 37(suppl_1):S20-S31. PubMed ID: 28388717
[TBL] [Abstract][Full Text] [Related]
23. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines.
Moers-Carpi M; Dirschka T; Feller-Heppt G; Hilton S; Hoffmann K; Philipp-Dormston WG; Rütter A; Tan K; Chapman MA; Fulford-Smith A
J Cosmet Laser Ther; 2012 Dec; 14(6):296-303. PubMed ID: 23057624
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of oral dexamethasone in the treatment of moderate to severe pharyngitis in children.
Olympia RP; Khine H; Avner JR
Arch Pediatr Adolesc Med; 2005 Mar; 159(3):278-82. PubMed ID: 15753273
[TBL] [Abstract][Full Text] [Related]
25. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
27. Diclofenac potassium liquid-filled soft gelatin capsules in the management of patients with postbunionectomy pain: a Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted over 5 days.
Riff DS; Duckor S; Gottlieb I; Diamond E; Soulier S; Raymond G; Boesing SE
Clin Ther; 2009 Oct; 31(10):2072-85. PubMed ID: 19922878
[TBL] [Abstract][Full Text] [Related]
28. Clinical Assessment of 2 Licensed AbobotulinumtoxinA Injection Volumes for the Treatment of Glabellar Lines.
Kaufman J; Cohen JL; Peredo MI; Jonas B; Down R; Nogueira A
Dermatol Surg; 2019 Oct; 45(10):1274-1284. PubMed ID: 30893159
[TBL] [Abstract][Full Text] [Related]
29. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
30. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
Lipton RB; Varon SF; Grosberg B; McAllister PJ; Freitag F; Aurora SK; Dodick DW; Silberstein SD; Diener HC; DeGryse RE; Nolan ME; Turkel CC
Neurology; 2011 Oct; 77(15):1465-72. PubMed ID: 21956721
[TBL] [Abstract][Full Text] [Related]
31. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics.
Kuo HC
Neurourol Urodyn; 2011 Sep; 30(7):1242-8. PubMed ID: 21560152
[TBL] [Abstract][Full Text] [Related]
32. Randomized Split-Face Study to Assess the Efficacy and Safety of AbobotulinumtoxinA Versus OnabotulinumtoxinA in the Treatment of Melomental Folds (Depressor Anguli Oris).
Fabi SG; Massaki AN; Guiha I; Goldman MP
Dermatol Surg; 2015 Nov; 41(11):1323-5. PubMed ID: 26506065
[No Abstract] [Full Text] [Related]
33. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
34. Retrospective review of 500 patients treated with abobotulinumtoxinA.
Hevia O
J Drugs Dermatol; 2010 Sep; 9(9):1081-4. PubMed ID: 20865838
[TBL] [Abstract][Full Text] [Related]
35. A two-phase, retrospective analysis evaluating efficacy of and patient satisfaction with abobotulinumtoxina used to treat dynamic facial rhytides.
Kiripolsky MG; Peterson JD; Guiha I; Goldman MP
Dermatol Surg; 2011 Oct; 37(10):1443-7. PubMed ID: 21649790
[TBL] [Abstract][Full Text] [Related]
36. The use of botulinum toxin type A in cosmetic facial procedures.
Jaspers GW; Pijpe J; Jansma J
Int J Oral Maxillofac Surg; 2011 Feb; 40(2):127-33. PubMed ID: 20965695
[TBL] [Abstract][Full Text] [Related]
37. OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines.
Cohen JL; Dayan SH; Cox SE; Yalamanchili R; Tardie G
Dermatol Surg; 2012 Sep; 38(9):1497-505. PubMed ID: 22621180
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of long-term botulinum toxin treatment for acquired cervical dystonia: a 25-year follow-up.
Petracca M; Lo Monaco MR; Ialongo T; Di Stasio E; Cerbarano ML; Maggi L; De Biase A; Di Lazzaro G; Calabresi P; Bentivoglio AR
J Neurol; 2023 Jan; 270(1):340-347. PubMed ID: 36068376
[TBL] [Abstract][Full Text] [Related]
39. Treatment of blepharospasm and Meige's syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice.
Jochim A; Meindl T; Huber C; Mantel T; Zwirner S; Castrop F; Haslinger B
J Neurol; 2020 Jan; 267(1):267-275. PubMed ID: 31630241
[TBL] [Abstract][Full Text] [Related]
40. Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment for Moderate to Severe Glabellar Lines.
Monheit GD; Baumann L; Maas C; Rand R; Down R
Dermatol Surg; 2020 Jan; 46(1):61-69. PubMed ID: 31356432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
